title: Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus.
abstract: The absence of expression of the p16INK4a gene product is observed in virtually all mesothelioma tumors and cell lines, whereas wild-type pRB expression is maintained. We have examined the potential therapeutic role of re-expressing the p16INK4a gene product in mice with established human mesothelioma xenografts. Experiments using Adp16 treatments in mesothelioma xenografts demonstrated prolonged survival and potential cure following treatment with p16INK4a-based gene therapy. These results demonstrate that p16INK4a gene transfer may play a therapeutic role in the treatment of mesothelioma.
authors: The Department of Medicine and Research Service, Minneapolis Veterans Affairs Medical Center, University of Minnesota Medical School, 55417, USA.
authors: S P
authors: SP
authors: Frizelle
authors: J B
authors: JB
authors: Rubins
authors: J X
authors: JX
authors: Zhou
authors: D T
authors: DT
authors: Curiel
authors: R A
authors: RA
authors: Kratzke
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D002352:Carrier Proteins / Q000235:genetics*; D002470:Cell Survival; D019941:Cyclin-Dependent Kinase Inhibitor p16; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D008654:Mesothelioma / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010641:Phenotype; D013997:Time Factors; D014407:Tumor Cells, Cultured
chemical_list: D002352:Carrier Proteins; D019941:Cyclin-Dependent Kinase Inhibitor p16